Eagle Pharmaceuticals Inc... (EGRX)
OTC: EGRX
· Real-Time Price · USD
1.25
-0.25 (-16.67%)
At close: Apr 04, 2025, 3:30 PM
Eagle Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 15.35M | 21.9M | 55.32M | 15.38M | 36.56M | 69.52M | 97.66M | 99.74M | 108.72M | 105.23M |
Short-Term Investments | n/a | n/a | n/a | n/a | 5.68M | 5.54M | 4.98M | 4.32M | n/a | n/a |
Long-Term Investments | 18.33M | 18.12M | 10.01M | 11.32M | 2.8M | 3.5M | 6.03M | 10.3M | 12.6M | 17.8M |
Other Long-Term Assets | 15.07M | 15.39M | 15.72M | 18.28M | 4.27M | 3.96M | 4.25M | 4.24M | 8.86M | 9.68M |
Receivables | 116.28M | 114.95M | 72.44M | 96.93M | 87.4M | 136.83M | 41.15M | 51.63M | 52.66M | 44.87M |
Inventory | 42.48M | 44.14M | 47.79M | 63.85M | 57.71M | 24.82M | 21.91M | 9.31M | 8.29M | 6.86M |
Other Current Assets | 3.82M | 11.5M | 13.2M | 8.88M | 2.9M | 4.76M | 5.64M | 2.43M | 4.46M | 7.03M |
Total Current Assets | 187.25M | 192.49M | 188.75M | 185.05M | 194.46M | 240.17M | 172.61M | 171.69M | 175.5M | 163.99M |
Property-Plant & Equipment | 1.01M | 1.12M | 1.17M | 1.3M | 1.46M | 1.63M | 1.64M | 1.77M | 1.97M | 2.27M |
Goodwill & Intangibles | 152.44M | 157.91M | 163.36M | 150.58M | 155.53M | 49.68M | 50.41M | 50.54M | 51.25M | 51.95M |
Total Long-Term Assets | 217.57M | 221.68M | 217.41M | 205.02M | 187.3M | 80M | 81.13M | 84.57M | 88.74M | 95.98M |
Total Assets | 404.82M | 414.18M | 406.16M | 390.07M | 381.76M | 320.17M | 253.73M | 256.26M | 264.24M | 259.97M |
Account Payables | 15.84M | 17.11M | 18.99M | 13.21M | 19.97M | 14.51M | 16.43M | 12.72M | 11.14M | 12.56M |
Deferred Revenue | n/a | n/a | n/a | n/a | 58.33M | n/a | 25.36M | n/a | n/a | n/a |
Short-Term Debt | 8.3M | 7.5M | 6.25M | 34.96M | 21.84M | 23.73M | 25.61M | 8M | 8M | 8M |
Other Current Liabilities | 2.46M | 3.32M | 10.84M | 18.49M | 7.34M | n/a | 6.18M | n/a | n/a | n/a |
Total Current Liabilities | 86.63M | 97.81M | 111.09M | 121.83M | 108.96M | 101.64M | 74.38M | 48.43M | 44.66M | 41.97M |
Long-Term Debt | 61.9M | 68.83M | 56.22M | 26.43M | 28.02M | n/a | n/a | 19.49M | 21.37M | 23.25M |
Other Long-Term Liabilities | 4.26M | 4.69M | 1.51M | n/a | n/a | n/a | -1K | n/a | n/a | n/a |
Total Long-Term Liabilities | 66.15M | 73.52M | 61.51M | 32.84M | 34.81M | 2.56M | 2.9M | 22.54M | 24.73M | 26.92M |
Total Liabilities | 152.78M | 171.33M | 172.6M | 154.67M | 143.77M | 104.2M | 77.28M | 70.97M | 69.39M | 68.89M |
Total Debt | 71.61M | 76.33M | 62.47M | 61.39M | 53.59M | 27.63M | 25.61M | 31.74M | 33.91M | 36.06M |
Common Stock | 18K | 18K | 18K | 18K | 18K | 17K | 17K | 17K | 17K | 17K |
Retained Earnings | 122.42M | 117.25M | 111.5M | 106.96M | 110.47M | 119.92M | 75.86M | 82.06M | 87.68M | 84.07M |
Comprehensive Income | -1.11M | -1.11M | -1.11M | 9.38M | 2.28M | 418K | -94K | -882K | -904K | 0.00 |
Shareholders Equity | 252.04M | 242.84M | 233.56M | 235.4M | 237.98M | 215.96M | 176.45M | 185.29M | 194.85M | 191.08M |
Total Investments | 18.33M | 18.12M | 10.01M | 11.32M | 2.8M | 5.54M | 4.98M | 4.32M | 12.6M | 17.8M |